Efficacy of acetylsalicylic acid in schizophrenia: a literature review
A. Aissa, S. Jedda, F. Askri, O. Maatouk, U. Ouali, Y. Zgueb, R. Jomli
TL;DR
This literature review examines whether acetylsalicylic acid (ASA) helps treat acute schizophrenia, finding some support for its use in early psychosis.
Contribution
The paper reviews existing studies to evaluate ASA as an adjuvant treatment for acute schizophrenia.
Findings
ASA showed efficacy in treating early psychosis in schizophrenia.
Illness duration may predict response to anti-inflammatory agents like ASA.
More research is needed on early-stage schizophrenia for better insights.
Abstract
There has been growing evidence to support the hypothesis that inflammation is involved in the pathogenesis of schizophrenia. The aim of the present literature review was to assess the efficacy of acetylsalicylic acid (ASA) as an adjuvant agent in the treatment of an acute exacerbation of schizophrenia. We searched randomized clinical trials based on regular searches of MEDLINE, Embase, PubMed. We included four studies. The results were in favor of the efficacy of ASA in the study where authors targeted early psychosis. Illness duration seems to predict response to anti-inflammatory agents. Further studies of early stages of schizophrenia are helpful. None Declared
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiet and metabolism studies · Cholesterol and Lipid Metabolism · Gastroesophageal reflux and treatments